Cabotegravir

Cabotegravir

Identifiers
CAS Number	1051375-10-0
3D model (Jmol)	Interactive image
ChemSpider	30829503
PubChem	54713659
UNII	HMH0132Z1Q
InChI InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1 Key: WCWSTNLSLKSJPK-LKFCYVNXSA-N InChI=1/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1 Key: WCWSTNLSLKSJPK-LKFCYVNXBF
SMILES C[C@H]1CO[C@H]2N1C(=O)c3c(c(=O)c(cn3C2)C(=O)NCc4ccc(cc4F)F)O
Properties
Chemical formula	C19H17F2N3O5
Molar mass	405.36 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
(what is  ?)
Infobox references

Cabotegravir (USAN^[1] and INN^[2]) (also known as S/GSK1265744 or GSK744) is an investigational new drug under development for the treatment of HIV infection. It is an integrase inhibitor, with a carbamoyl pyridone structure similar to dolutegravir.^[3] In investigational studies, the agent has been packaged into nanoparticles (GSK744LAP) conferring an exceptionally long half-life of 21–50 days following a single dose. In theory, this would make possible suppression of HIV with dosing as infrequently as once every three months.^[4]

References

1. "Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014.
2. "WHO Drug Information, Vol. 28, No. 2, 2014" (PDF). WHO Publications. Retrieved 19 September 2014.
3. Borrell, Brendan (2014). "Long-acting shot prevents infection with HIV analogue". Nature. doi:10.1038/nature.2014.14819.
4. PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.